EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration

Andrew Callan, Justin Heckman iD, Giani Tah, Samantha Lopez, Laura Valdez, Andrew Tsin iD

International Journal of Molecular Sciences · 22.05.2025 · 26 (11) · 4992

DOI: 10.3390/ijms26114992 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.05.2025. Verfasst von Andrew Callan und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78539, USA. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Vascular Endothelial Growth Factor A, Macular Degeneration. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NEI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis throughout the human body, influencing countless physiological and pathological processes, including tumor growth, preeclampsia, and retinal diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). In DR, VEGF promotes retinal neovascularization and intraretinal fluid accumulation, leading to complications like diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Regular intravitreal anti-VEGF injections are commonly used to manage PDR and DME, though repeated treatments are often required, and efficacy can be limited. AMD, a major cause of vision loss in older adults, is characterized by either dry or wet forms. While the dry form has not been shown to be influenced by VEGF, the choroidal neovascularization of wet AMD has strong associations with VEGF. Current treatment for wet AMD consists primarily of anti-VEGF injections, the gold standard of care, but is limited by varying patient responses, as treatments are often repeated every 4-8 weeks indefinitely. This review explores the pathogenic role of VEGF in both DR and AMD, discussing the molecular mechanisms underlying these diseases and the therapeutic approaches targeting VEGF. Despite advancements, the variability in treatment responses highlights the need for continued research to develop more effective therapies to prevent vision loss and blindness associated with these retinal diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyVascular Endothelial Growth Factor AMacular DegenerationHumansAnimalsAngiogenesis InhibitorsChoroidal Neovascularization

Stichwörter der Autor:innen

AMDDROphthalmologyVEGFage-related macular degenerationdiabetic retinopathyvascular endothelial growth factor

Substanzen

Vascular Endothelial Growth Factor AAngiogenesis InhibitorsVEGFA protein, human

Autor:innen und Institutionen

  • School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78539, USA.

ORCID-Profile: Justin Heckman, Andrew Tsin

Förderung

  • NCI NIH HHS
  • NEI NIH HHS
  • NIH HHS
  • NIDA NIH HHS
  • NIH

Zitieren

APA

Callan, A., Heckman, J., Tah, G., Lopez, S., Valdez, L., & Tsin, A. (2025). VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration. International Journal of Molecular Sciences, 26(11), 4992. https://doi.org/10.3390/ijms26114992

Vancouver

Callan A, Heckman J, Tah G, Lopez S, Valdez L, Tsin A. VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration. International Journal of Molecular Sciences. 2025;26(11):4992. doi:10.3390/ijms26114992

BibTeX
@article{Callan2025,
  author = {Callan, Andrew and Heckman, Justin and Tah, Giani and Lopez, Samantha and Valdez, Laura and Tsin, Andrew},
  title = {VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {11},
  pages = {4992},
  doi = {10.3390/ijms26114992}
}
Kostenlos starten →